228 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
for various products, including the Company's retinal franchise, partly offset by lower contributions to an independent not-for-profit patient
SC TO-T
DBTX
Decibel Therapeutics, Inc.
25 Aug 23
Third party tender offer statement
7:46am
& Katz
51 West 52nd Street
New York, NY 10019
(212) 403-1000
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify
SC TO-C
zjaton7monwm e7u9y
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
wn8w1yukeedeua3i651
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-10.3
p14t1ih
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
c7qd6z9z
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
ec6fr
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
9rnt5320
20 Dec 22
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-99.1
kls55arxio
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
8-K
EX-99.1
4pa1lf7 emhz722
3 Aug 22
Regeneron Reports Second Quarter 2022 Financial and Operating Results
7:08am
8-K
EX-99.1
pkb6qt7d0fujlmc5izsl
4 May 22
Regeneron Reports First Quarter 2022 Financial and Operating Results
7:08am
SC TO-T
n21l90
2 May 22
Third party tender offer statement
7:48am